Review



goat polyclonal anti mouse taci  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 85
      Buy from Supplier

    Structured Review

    R&D Systems goat polyclonal anti mouse taci
    Goat Polyclonal Anti Mouse Taci, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/bio_rxiv__2025__09__05__674478-290-14-19?v=R%26D+Systems
    Average 85 stars, based on 4 article reviews
    goat polyclonal anti mouse taci - by Bioz Stars, 2026-07
    85/100 stars

    Images



    Similar Products

    cd267 (taci) antibody, anti-mouse, reafinity  (Miltenyi Biotec)
    96
    Miltenyi Biotec cd267 (taci) antibody, anti-mouse, reafinity
    Cd267 (Taci) Antibody, Anti Mouse, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/miltenyi+biotec___130-124-100?v=Miltenyi+Biotec
    Average 96 stars, based on 1 article reviews
    cd267 (taci) antibody, anti-mouse, reafinity - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    anti c casp3  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc anti c casp3
    Anti C Casp3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/pmc12748583-318-29-45?v=Cell+Signaling+Technology+Inc
    Average 95 stars, based on 1 article reviews
    anti c casp3 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    goat polyclonal anti mouse taci  (R&D Systems)
    85
    R&D Systems goat polyclonal anti mouse taci
    Goat Polyclonal Anti Mouse Taci, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/bio_rxiv__2025__09__05__674478-290-14-19?v=R%26D+Systems
    Average 85 stars, based on 1 article reviews
    goat polyclonal anti mouse taci - by Bioz Stars, 2026-07
    85/100 stars
    		  Buy from Supplier
    anti taci  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc anti taci
    AKT-mTORC1 signaling is impaired in <t>TACI</t> KO MZ B cells. A. Flow cytometry histograms comparing pAKT-T308 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). B. pAKT-T308 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. WT:WT n = 4 and KO:WT n = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. C. Flow cytometry histograms comparing pAKT-S473 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). D. pAKT-S473 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. n = 4, from one of two independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. E. Flow cytometry plots and histograms comparing pS6-S235/236 levels in WT and TACI KO CD45.2 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT cells stained with isotype control antibody (Isotype). F. The percentage of pS6 + cells (left) and pS6 MFI within pS6 + cells (right), measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. N = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. G. Immunoblot anti-TACI immunoprecipitation (IP) from LPS-activated B cells, alongside a control IP using isotype-control antibody (IC) and the input cell lysates. Cells were stimulated with APRIL, BAFF or media-only control for 15 min at 37°C. The immunoblot was probed with <t>anti-TACI,</t> <t>anti-p110δ,</t> anti-p85α and anti-mTOR. The same membrane sections are displayed at two different image intensities for p110δ, p85α and mTOR due to higher protein levels in the input lysates. Representative of two independent experiments.
    Anti Taci, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/bio_rxiv__2025__09__05__674478-293-40-43?v=Cell+Signaling+Technology+Inc
    Average 93 stars, based on 1 article reviews
    anti taci - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    6d5  (R&D Systems)
    85
    R&D Systems 6d5
    AKT-mTORC1 signaling is impaired in <t>TACI</t> KO MZ B cells. A. Flow cytometry histograms comparing pAKT-T308 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). B. pAKT-T308 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. WT:WT n = 4 and KO:WT n = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. C. Flow cytometry histograms comparing pAKT-S473 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). D. pAKT-S473 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. n = 4, from one of two independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. E. Flow cytometry plots and histograms comparing pS6-S235/236 levels in WT and TACI KO CD45.2 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT cells stained with isotype control antibody (Isotype). F. The percentage of pS6 + cells (left) and pS6 MFI within pS6 + cells (right), measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. N = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. G. Immunoblot anti-TACI immunoprecipitation (IP) from LPS-activated B cells, alongside a control IP using isotype-control antibody (IC) and the input cell lysates. Cells were stimulated with APRIL, BAFF or media-only control for 15 min at 37°C. The immunoblot was probed with <t>anti-TACI,</t> <t>anti-p110δ,</t> anti-p85α and anti-mTOR. The same membrane sections are displayed at two different image intensities for p110δ, p85α and mTOR due to higher protein levels in the input lysates. Representative of two independent experiments.
    6d5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/pmc11260164__pnas__2404309121__sapp-71-130-149?v=R%26D+Systems
    Average 85 stars, based on 1 article reviews
    6d5 - by Bioz Stars, 2026-07
    85/100 stars
    		  Buy from Supplier
    cleaved capase 3  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc cleaved capase 3
    AKT-mTORC1 signaling is impaired in <t>TACI</t> KO MZ B cells. A. Flow cytometry histograms comparing pAKT-T308 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). B. pAKT-T308 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. WT:WT n = 4 and KO:WT n = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. C. Flow cytometry histograms comparing pAKT-S473 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). D. pAKT-S473 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. n = 4, from one of two independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. E. Flow cytometry plots and histograms comparing pS6-S235/236 levels in WT and TACI KO CD45.2 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT cells stained with isotype control antibody (Isotype). F. The percentage of pS6 + cells (left) and pS6 MFI within pS6 + cells (right), measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. N = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. G. Immunoblot anti-TACI immunoprecipitation (IP) from LPS-activated B cells, alongside a control IP using isotype-control antibody (IC) and the input cell lysates. Cells were stimulated with APRIL, BAFF or media-only control for 15 min at 37°C. The immunoblot was probed with <t>anti-TACI,</t> <t>anti-p110δ,</t> anti-p85α and anti-mTOR. The same membrane sections are displayed at two different image intensities for p110δ, p85α and mTOR due to higher protein levels in the input lysates. Representative of two independent experiments.
    Cleaved Capase 3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/pm40404214-410-28-32?v=Cell+Signaling+Technology+Inc
    Average 95 stars, based on 1 article reviews
    cleaved capase 3 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    rabbit anti cleaved caspase3  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc rabbit anti cleaved caspase3
    AKT-mTORC1 signaling is impaired in <t>TACI</t> KO MZ B cells. A. Flow cytometry histograms comparing pAKT-T308 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). B. pAKT-T308 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. WT:WT n = 4 and KO:WT n = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. C. Flow cytometry histograms comparing pAKT-S473 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). D. pAKT-S473 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. n = 4, from one of two independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. E. Flow cytometry plots and histograms comparing pS6-S235/236 levels in WT and TACI KO CD45.2 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT cells stained with isotype control antibody (Isotype). F. The percentage of pS6 + cells (left) and pS6 MFI within pS6 + cells (right), measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. N = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. G. Immunoblot anti-TACI immunoprecipitation (IP) from LPS-activated B cells, alongside a control IP using isotype-control antibody (IC) and the input cell lysates. Cells were stimulated with APRIL, BAFF or media-only control for 15 min at 37°C. The immunoblot was probed with <t>anti-TACI,</t> <t>anti-p110δ,</t> anti-p85α and anti-mTOR. The same membrane sections are displayed at two different image intensities for p110δ, p85α and mTOR due to higher protein levels in the input lysates. Representative of two independent experiments.
    Rabbit Anti Cleaved Caspase3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/pm39978252-96-50-54?v=Cell+Signaling+Technology+Inc
    Average 95 stars, based on 1 article reviews
    rabbit anti cleaved caspase3 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    taci  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology taci
    The effect of <t> CCN1 </t> on gene expression of APRIL/BAFF system (fold change).
    Taci, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/pmc11730293-182-20-30?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    taci - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    baff  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology baff
    Fig. 1. The effect <t>of</t> <t>CCN1</t> treatment on protein expression of <t>APRIL/BAFF</t> system. (A) Western blot analyses show that treatment with recombinant CCN1 (rCCN1) at 1 µg/ml for 6 h promotes APRIL and BAFF expression in both ESCC (KYSE150 and KYSE410) and EAC (OE19 and OE33). (B) Quantitative analysis of protein expression of the APRIL/BAFF system in OE33 based on at least 3 replicates. (C) Quantitative analysis of protein expression of the APRIL/BAFF system in OE19 based on at least 3 replicates. (D) Quantitative analysis of protein expression of the APRIL/BAFF system in KYSE150 based on at least 3 replicates. (E) Quantitative analysis of protein expression of the APRIL/BAFF system in KYSE410 based on at least 3 replicates. *Statistical significance. M – molecular weight ladder.
    Baff, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/taci+antibody/pm39806221-181-18-30?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    baff - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    AKT-mTORC1 signaling is impaired in TACI KO MZ B cells. A. Flow cytometry histograms comparing pAKT-T308 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). B. pAKT-T308 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. WT:WT n = 4 and KO:WT n = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. C. Flow cytometry histograms comparing pAKT-S473 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). D. pAKT-S473 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. n = 4, from one of two independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. E. Flow cytometry plots and histograms comparing pS6-S235/236 levels in WT and TACI KO CD45.2 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT cells stained with isotype control antibody (Isotype). F. The percentage of pS6 + cells (left) and pS6 MFI within pS6 + cells (right), measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. N = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. G. Immunoblot anti-TACI immunoprecipitation (IP) from LPS-activated B cells, alongside a control IP using isotype-control antibody (IC) and the input cell lysates. Cells were stimulated with APRIL, BAFF or media-only control for 15 min at 37°C. The immunoblot was probed with anti-TACI, anti-p110δ, anti-p85α and anti-mTOR. The same membrane sections are displayed at two different image intensities for p110δ, p85α and mTOR due to higher protein levels in the input lysates. Representative of two independent experiments.

    Journal: bioRxiv

    Article Title: TACI Regulates Marginal Zone B Cell Development

    doi: 10.1101/2025.09.05.674478

    Figure Lengend Snippet: AKT-mTORC1 signaling is impaired in TACI KO MZ B cells. A. Flow cytometry histograms comparing pAKT-T308 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). B. pAKT-T308 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. WT:WT n = 4 and KO:WT n = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. C. Flow cytometry histograms comparing pAKT-S473 levels in TACI KO CD45.2 + , WT CD45.2 + and WT CD45.1 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Red: TACI KO CD45.2 + MZ; black: WT CD45.2 + MZ; grey: WT CD45.1 + ; dashed lines: cells treated with the PI3Kδ inhibitor idelalisib (PI3Ki). D. pAKT-S473 MFI, measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. n = 4, from one of two independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. E. Flow cytometry plots and histograms comparing pS6-S235/236 levels in WT and TACI KO CD45.2 + resting MZ B cells at 37°C from WT:WT and KO:WT chimeras. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT cells stained with isotype control antibody (Isotype). F. The percentage of pS6 + cells (left) and pS6 MFI within pS6 + cells (right), measured by flow cytometry, in CD45.2 + and CD45.1 + resting MZ B cells from WT:WT and KO:WT chimeras. N = 5, from one of four independent experiments. Lines connect cells from the same sample. Black: WT CD45.2 + ; red: TACI KO CD45.2 + ; grey: WT CD45.1 + . Numbers above graphs indicate p-values where p≤0.05 otherwise no value is shown, as determined by repeated measures two-way ANOVA with Fisher’s LSD test. G. Immunoblot anti-TACI immunoprecipitation (IP) from LPS-activated B cells, alongside a control IP using isotype-control antibody (IC) and the input cell lysates. Cells were stimulated with APRIL, BAFF or media-only control for 15 min at 37°C. The immunoblot was probed with anti-TACI, anti-p110δ, anti-p85α and anti-mTOR. The same membrane sections are displayed at two different image intensities for p110δ, p85α and mTOR due to higher protein levels in the input lysates. Representative of two independent experiments.

    Article Snippet: Membranes were blocked with 5% BSA in TBST (TBS, 0.001% Tween 20) for 1 h at room temperature then incubated sequentially with primary antibodies: anti-mTOR (4517, Cell Signaling Technology), anti- p110δ (34050, Cell Signaling Technology), anti-p85α (4257, Cell Signaling Technology), anti- TACI (93005, Cell Signaling Technology), anti-MyD88 (4283, Cell Signaling Technology) in 5% BSA TBST overnight at 4°C.

    Techniques: Flow Cytometry, Staining, Control, Western Blot, Immunoprecipitation, Membrane

    The effect of CCN1 on gene expression of APRIL/BAFF system (fold change).

    Journal: Scientific Reports

    Article Title: CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma

    doi: 10.1038/s41598-025-86228-z

    Figure Lengend Snippet: The effect of CCN1 on gene expression of APRIL/BAFF system (fold change).

    Article Snippet: The following primary antibodies were used in this study: CCN1 (TA349858) and BCMA (TA382649) from Origene, APRIL (sc-374674), BAFF (sc-271809), TACI (sc-365253), BAFFR (sc-365409), Furin (sc-133142), and β-actin (sc69879) from Santa Cruz Biotechnology.

    Techniques: Gene Expression

    Fig. 1. The effect of CCN1 treatment on protein expression of APRIL/BAFF system. (A) Western blot analyses show that treatment with recombinant CCN1 (rCCN1) at 1 µg/ml for 6 h promotes APRIL and BAFF expression in both ESCC (KYSE150 and KYSE410) and EAC (OE19 and OE33). (B) Quantitative analysis of protein expression of the APRIL/BAFF system in OE33 based on at least 3 replicates. (C) Quantitative analysis of protein expression of the APRIL/BAFF system in OE19 based on at least 3 replicates. (D) Quantitative analysis of protein expression of the APRIL/BAFF system in KYSE150 based on at least 3 replicates. (E) Quantitative analysis of protein expression of the APRIL/BAFF system in KYSE410 based on at least 3 replicates. *Statistical significance. M – molecular weight ladder.

    Journal: Scientific reports

    Article Title: CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma.

    doi: 10.1038/s41598-025-86228-z

    Figure Lengend Snippet: Fig. 1. The effect of CCN1 treatment on protein expression of APRIL/BAFF system. (A) Western blot analyses show that treatment with recombinant CCN1 (rCCN1) at 1 µg/ml for 6 h promotes APRIL and BAFF expression in both ESCC (KYSE150 and KYSE410) and EAC (OE19 and OE33). (B) Quantitative analysis of protein expression of the APRIL/BAFF system in OE33 based on at least 3 replicates. (C) Quantitative analysis of protein expression of the APRIL/BAFF system in OE19 based on at least 3 replicates. (D) Quantitative analysis of protein expression of the APRIL/BAFF system in KYSE150 based on at least 3 replicates. (E) Quantitative analysis of protein expression of the APRIL/BAFF system in KYSE410 based on at least 3 replicates. *Statistical significance. M – molecular weight ladder.

    Article Snippet: The following primary antibodies were used in this study: CCN1 (TA349858) and BCMA (TA382649) from Origene, APRIL (sc-374674), BAFF (sc-271809), TACI (sc-365253), BAFFR (sc365409), Furin (sc-133142), and β-actin (sc69879) from Santa Cruz Biotechnology.

    Techniques: Expressing, Western Blot, Recombinant, Molecular Weight

    Fig. 3. Expression of APRIL, BAFF, and BCMA in KYSE150 in response to CCN1 transfection. (A) Upper panel: Immunoprecipitation (IP) of soluble APRIL (sAPRIL) from the cell culture media. Middle panel: Western blot analyses of cell extracts show APRIL precursor (27kD) and its cleaved products: soluble APRIL (sAPRIL) and cellular residue (cAPRIL). (B) Quantitative analysis of APRIL expression and cleavage in KYSE150 in response to CCN1 transfection, based on at least 3 replicates. (C) Upper panel: Immunoprecipitation (IP) of soluble BAFF (sBAFF) from the cell culture media. Middle panel: Western blot analyses of cell extracts show BAFF precursor (31kD) and its cleaved products: soluble BAFF (sBAFF) and cellular residue (cBAFF). (D) Quantitative analysis of BAFF expression and cleavage in KYSE150 in response to CCN1 transfection, based on at least 3 replicates. (E) Western blot analyses of cell extracts show BCMA expression in KYSE150. (F) Quantitative analysis of BCMA expression in KYSE150 in response to CCN1 transfection, based on at least 3 replicates.* Statistical significance. M – molecular weight ladder.

    Journal: Scientific reports

    Article Title: CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma.

    doi: 10.1038/s41598-025-86228-z

    Figure Lengend Snippet: Fig. 3. Expression of APRIL, BAFF, and BCMA in KYSE150 in response to CCN1 transfection. (A) Upper panel: Immunoprecipitation (IP) of soluble APRIL (sAPRIL) from the cell culture media. Middle panel: Western blot analyses of cell extracts show APRIL precursor (27kD) and its cleaved products: soluble APRIL (sAPRIL) and cellular residue (cAPRIL). (B) Quantitative analysis of APRIL expression and cleavage in KYSE150 in response to CCN1 transfection, based on at least 3 replicates. (C) Upper panel: Immunoprecipitation (IP) of soluble BAFF (sBAFF) from the cell culture media. Middle panel: Western blot analyses of cell extracts show BAFF precursor (31kD) and its cleaved products: soluble BAFF (sBAFF) and cellular residue (cBAFF). (D) Quantitative analysis of BAFF expression and cleavage in KYSE150 in response to CCN1 transfection, based on at least 3 replicates. (E) Western blot analyses of cell extracts show BCMA expression in KYSE150. (F) Quantitative analysis of BCMA expression in KYSE150 in response to CCN1 transfection, based on at least 3 replicates.* Statistical significance. M – molecular weight ladder.

    Article Snippet: The following primary antibodies were used in this study: CCN1 (TA349858) and BCMA (TA382649) from Origene, APRIL (sc-374674), BAFF (sc-271809), TACI (sc-365253), BAFFR (sc365409), Furin (sc-133142), and β-actin (sc69879) from Santa Cruz Biotechnology.

    Techniques: Expressing, Transfection, Immunoprecipitation, Cell Culture, Western Blot, Residue, Molecular Weight

    Fig. 4. Expression of APRIL, BAFF, and BCMA in OE19 in response to CCN1 transfection. (A) Upper panel: Immunoprecipitation (IP) of soluble APRIL (sAPRIL) from the cell culture media. Middle panel: Western blot analyses of cell extracts show APRIL precursor (27kD) and its cleaved products: soluble APRIL (sAPRIL) and cellular residue (cAPRIL). (B) Quantitative analysis of APRIL expression and cleavage in OE19 in response to CCN1 transfection, based on at least 3 replicates. (C) Upper panel: Immunoprecipitation (IP) of soluble BAFF (sBAFF) from the cell culture media.Middle panel: Western blot analyses of cell extracts show BAFF precursor (31kD) and its cleaved products: soluble BAFF (sBAFF) and cellular residue (cBAFF). (D) Quantitative analysis of BAFF expression and cleavage in OE19 in response to CCN1 transfection, based on at least 3 replicates. (E) Western blot analyses of cell extracts show BCMA expression in OE19. (F) Quantitative analysis of BCMA expression in OE19 in response to CCN1 transfection, based on at least 3 replicates.* Statistical significance. M – molecular weight ladder.

    Journal: Scientific reports

    Article Title: CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma.

    doi: 10.1038/s41598-025-86228-z

    Figure Lengend Snippet: Fig. 4. Expression of APRIL, BAFF, and BCMA in OE19 in response to CCN1 transfection. (A) Upper panel: Immunoprecipitation (IP) of soluble APRIL (sAPRIL) from the cell culture media. Middle panel: Western blot analyses of cell extracts show APRIL precursor (27kD) and its cleaved products: soluble APRIL (sAPRIL) and cellular residue (cAPRIL). (B) Quantitative analysis of APRIL expression and cleavage in OE19 in response to CCN1 transfection, based on at least 3 replicates. (C) Upper panel: Immunoprecipitation (IP) of soluble BAFF (sBAFF) from the cell culture media.Middle panel: Western blot analyses of cell extracts show BAFF precursor (31kD) and its cleaved products: soluble BAFF (sBAFF) and cellular residue (cBAFF). (D) Quantitative analysis of BAFF expression and cleavage in OE19 in response to CCN1 transfection, based on at least 3 replicates. (E) Western blot analyses of cell extracts show BCMA expression in OE19. (F) Quantitative analysis of BCMA expression in OE19 in response to CCN1 transfection, based on at least 3 replicates.* Statistical significance. M – molecular weight ladder.

    Article Snippet: The following primary antibodies were used in this study: CCN1 (TA349858) and BCMA (TA382649) from Origene, APRIL (sc-374674), BAFF (sc-271809), TACI (sc-365253), BAFFR (sc365409), Furin (sc-133142), and β-actin (sc69879) from Santa Cruz Biotechnology.

    Techniques: Expressing, Transfection, Immunoprecipitation, Cell Culture, Western Blot, Residue, Molecular Weight

    Fig. 5. Analyses of APRIL and BAFF binding to BCMA in EAC versus ESCC cells in response to CCN1 transfection. (A) Immunoprecipitation (IP) of BCMA from the cell extracts of OE19 and KYSE150 and Western blot analyses for its association with APRIL and BAFF. (B) Quantitative analysis of APRIL/BAFF binding to BCMA in OE19, based on at least 3 replicates. (C) Quantitative analysis of APRIL/BAFF binding to BCMA in KYSE150, based on at least 3 replicates. *Statistical significance. M – molecular weight ladder. (D) ESCC and EAC cells were transfected with pcDNA3.1-CCN1 or the empty vector (control) and then stained with the specific antibody for either APRIL, BAFF, or BCMA. Upper and middle panel: KYSE150 and OE19 cells were double-stained with a mouse-anti-APRIL antibody and a rabbit-anti-BCMA antibody. The fluorescence signal was generated using a Texas Red-conjugated goat-anti-mouse antibody (red) and a FITC- conjugated goat-anti-rabbit antibody (green). Lower panel: OE33 cells were first stained with a mouse-anti- BAFF antibody and then incubated with a FITC-conjugated goat-anti-mouse antibody (green). The nuclei were counterstained with propidium iodide (red).

    Journal: Scientific reports

    Article Title: CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma.

    doi: 10.1038/s41598-025-86228-z

    Figure Lengend Snippet: Fig. 5. Analyses of APRIL and BAFF binding to BCMA in EAC versus ESCC cells in response to CCN1 transfection. (A) Immunoprecipitation (IP) of BCMA from the cell extracts of OE19 and KYSE150 and Western blot analyses for its association with APRIL and BAFF. (B) Quantitative analysis of APRIL/BAFF binding to BCMA in OE19, based on at least 3 replicates. (C) Quantitative analysis of APRIL/BAFF binding to BCMA in KYSE150, based on at least 3 replicates. *Statistical significance. M – molecular weight ladder. (D) ESCC and EAC cells were transfected with pcDNA3.1-CCN1 or the empty vector (control) and then stained with the specific antibody for either APRIL, BAFF, or BCMA. Upper and middle panel: KYSE150 and OE19 cells were double-stained with a mouse-anti-APRIL antibody and a rabbit-anti-BCMA antibody. The fluorescence signal was generated using a Texas Red-conjugated goat-anti-mouse antibody (red) and a FITC- conjugated goat-anti-rabbit antibody (green). Lower panel: OE33 cells were first stained with a mouse-anti- BAFF antibody and then incubated with a FITC-conjugated goat-anti-mouse antibody (green). The nuclei were counterstained with propidium iodide (red).

    Article Snippet: The following primary antibodies were used in this study: CCN1 (TA349858) and BCMA (TA382649) from Origene, APRIL (sc-374674), BAFF (sc-271809), TACI (sc-365253), BAFFR (sc365409), Furin (sc-133142), and β-actin (sc69879) from Santa Cruz Biotechnology.

    Techniques: Binding Assay, Transfection, Immunoprecipitation, Western Blot, Molecular Weight, Plasmid Preparation, Control, Staining, Fluorescence, Generated, Incubation

    Fig. 6. The effect of CCN1 expression on Furin activity. (A) Western blot analyses show active Furin (58 kD) and the cleaved prodomain (38 kD) in response to CCN1 transfection (pCCN1) in OE19 and KYSE150. (B) Quantitative analysis of active Furin based on at least 3 replicates. (C) Immunoprecipitation (IP) of BCMA from the cell extracts of OE19 and Western blot analyses for its association with APRIL and BAFF with or without the addition of recombinant active Furin (rFurin). (D) Western blot analyses of BCMA input. *Statistical significance. M – molecular weight ladder.

    Journal: Scientific reports

    Article Title: CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma.

    doi: 10.1038/s41598-025-86228-z

    Figure Lengend Snippet: Fig. 6. The effect of CCN1 expression on Furin activity. (A) Western blot analyses show active Furin (58 kD) and the cleaved prodomain (38 kD) in response to CCN1 transfection (pCCN1) in OE19 and KYSE150. (B) Quantitative analysis of active Furin based on at least 3 replicates. (C) Immunoprecipitation (IP) of BCMA from the cell extracts of OE19 and Western blot analyses for its association with APRIL and BAFF with or without the addition of recombinant active Furin (rFurin). (D) Western blot analyses of BCMA input. *Statistical significance. M – molecular weight ladder.

    Article Snippet: The following primary antibodies were used in this study: CCN1 (TA349858) and BCMA (TA382649) from Origene, APRIL (sc-374674), BAFF (sc-271809), TACI (sc-365253), BAFFR (sc365409), Furin (sc-133142), and β-actin (sc69879) from Santa Cruz Biotechnology.

    Techniques: Expressing, Activity Assay, Western Blot, Transfection, Immunoprecipitation, Recombinant, Molecular Weight

    Fig. 7. Cell proliferation assays using CCK-8 kit in response to treatment with either recombinant CCN1 (rCCN1), recombinant APRIL (rAPRIL), recombinant BAFF (rBAFF), or recombinant CCN1 (rCCN1) plus recombinant active Furin (rFurin). (A) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant CCN1 for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (B) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant CCN1 plus recombinant active Furin for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (C) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant CCN1 plus recombinant active Furin for up to 24 h, and then Furin was replenished as indicated by the arrow. Based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (D) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant APRIL for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (E) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant BAFF for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (F) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant APRIL for up to 24 h, and then APRIL was replenished as indicated by the arrow. Based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (G) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant BAFF for up to 24 h, and then BAFF was replenished as indicated by the arrow. Based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. *Statistical significance.

    Journal: Scientific reports

    Article Title: CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma.

    doi: 10.1038/s41598-025-86228-z

    Figure Lengend Snippet: Fig. 7. Cell proliferation assays using CCK-8 kit in response to treatment with either recombinant CCN1 (rCCN1), recombinant APRIL (rAPRIL), recombinant BAFF (rBAFF), or recombinant CCN1 (rCCN1) plus recombinant active Furin (rFurin). (A) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant CCN1 for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (B) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant CCN1 plus recombinant active Furin for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (C) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant CCN1 plus recombinant active Furin for up to 24 h, and then Furin was replenished as indicated by the arrow. Based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (D) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant APRIL for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (E) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant BAFF for up to 48 h based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (F) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant APRIL for up to 24 h, and then APRIL was replenished as indicated by the arrow. Based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. (G) Quantitative analysis of the relative cell numbers of OE19, OE33, KYSE150, and KYSE410 after incubation with recombinant BAFF for up to 24 h, and then BAFF was replenished as indicated by the arrow. Based on at least 3 replicates. The initial number of cells was set to 100 arbitrarily. *Statistical significance.

    Article Snippet: The following primary antibodies were used in this study: CCN1 (TA349858) and BCMA (TA382649) from Origene, APRIL (sc-374674), BAFF (sc-271809), TACI (sc-365253), BAFFR (sc365409), Furin (sc-133142), and β-actin (sc69879) from Santa Cruz Biotechnology.

    Techniques: CCK-8 Assay, Recombinant, Incubation